High on treatment platelet reactivity

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard after percutaneous coronary intervention (PCI).
• Despite DAPT, ischemic events, including stent thrombosis, persist and are associated with high mortality.
• Inter-individual variability in clopidogrel response leads to high on-treatment platelet reactivity (HTPR) in 4-46% of patients.

Purpose of the Study:

• To summarize the current understanding of high on-treatment platelet reactivity (HTPR) in patients undergoing PCI.
• To highlight the association between HTPR and adverse ischemic events post-PCI.
• To address the ongoing debate regarding the routine assessment and clinical interpretation of platelet reactivity.

Main Methods:

• Review of recent studies and clinical data.
• Analysis of the relationship between clopidogrel response and ischemic events.
• Discussion of the challenges in assessing and utilizing platelet reactivity measurements in clinical practice.

Main Results:

• A significant association exists between HTPR and increased risk of ischemic events in PCI patients.
• HTPR prevalence varies widely (4-46%), indicating substantial inter-individual differences in clopidogrel efficacy.
• Current methods for assessing platelet reactivity and guiding treatment decisions remain controversial.

Conclusions:

• HTPR is a significant clinical issue in patients treated with clopidogrel after PCI.
• Further research and standardized guidelines are needed for effective management of HTPR.
• Optimizing antiplatelet therapy based on individual response is crucial to reduce cardiovascular events and stent thrombosis.